Abstract
Summary
Background: Severe acute pancreatitis (SAP) is characterized by extensive acinar-cell injury, metabolic dysregulation, and systemic inflammatory activation. Reliable biochemical markers for early risk stratification remain limited. Lactate dehydrogenase (LDH) and amylase (AMY), routinely measured enzymes reflecting cellular damage and pancreatic exocrine dysfunction, may provide prognostic value. To evaluate the diagnostic performance of serum LDH and AMY in identifying SAP and predicting short-term outcomes.
Methods: This retrospective study included 200 patients with acute pancreatitis. Serum LDH and AMY were measured on admission using standardized clinical chemistry assays with internal quality control. Patients were categorized as MAP, MSAP, or SAP, and SAP cases were further stratified into good and poor 2-week prognosis groups. Logistic regression and ROC analyses were used to determine the predictive value of LDH and AMY.
Results: LDH and AMY levels increased significantly with disease severity (P<0.05). Both biomarkers were independent predictors of SAP (LDH OR=1.644; AMY OR=1.670) and poor prognosis (LDH OR=1.684; AMY OR=1.730). Combined LDH+AMY demonstrated superior predictive accuracy for SAP (AUC=0.854) and short-term poor prognosis (AUC=0.884), outperforming individual markers.
Conclusions: Serum LDH and AMY are clinically valuable biochemical indicators for early identification of SAP and prediction of short-term outcomes. Their combined use significantly enhances diagnostic accuracy, supporting their integration into early biochemical risk assessment models.
Keywords
Array
Array
Array
Array
Array
References
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.